Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Summary

This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-04-01

Primary completion

2022-11-17

Completion

2024-07-31

Outcome

Outcome not reported

Stopped (Business): “Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.”

Drugs

Indications